Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Discovery and Transgenomic Collaborate

Published: Thursday, January 16, 2014
Last Updated: Thursday, January 16, 2014
Bookmark and Share
Collaboration agreement aims to develop improved genetic diagnostic tests incorporating state of the art controls.

The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon’s Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in future.

Under the terms of the agreement, Horizon will provide its renewable, genetically defined Quantitative Molecular Reference Standards in both gDNA (genomic DNA) and FFPE (formalin fixed paraffin embedded) format, via its Horizon Diagnostics division. The Quantitative Molecular Reference Standards will be used as advanced reference standards for Transgenomic’s range of genetic diagnostic tests, and in the development of novel tests and in vitro diagnostic testing kits. The Quantitative Molecular Reference Standard products will be chosen from Horizon Diagnostics’ existing inventory of over 300 products, and Horizon’s GENESIS™ gene editing platform will also be employed to precisely engineer new lines as needed, to support the development of the new tests and kits. 

“Combining Horizon’s technology for developing reliable, genetically defined Quantitative Molecular Reference Standards, with Transgenomic’s expertise in molecular diagnostic technologies, this collaboration provides strategic opportunities that will significantly benefit our biomarker identification business,” said Paul Kinnon, President and Chief Executive Officer of Transgenomic.  “We are excited to be working with Horizon, a leader in the personalized medicine field, as we work to expand our test and kit offerings in the rapidly growing area of companion diagnostics.”

“Transgenomic operates at the cutting edge of molecular diagnostics and is an ideal partner for Horizon,” said Paul Morrill, Senior Vice President of Horizon Diagnostics.  “This collaboration adds to our strong network of world class partners practicing high quality science, and contributes to our goal of advancing personalized medicine and ultimately better patient care.  We look forward to working with the Transgenomic team.”

Horizon Diagnostics’ Reference Standard product portfolio comprises highly validated, engineered cell line derived material, including purified DNA with matched normal and renewable formalin fixed, paraffin embedded samples. The available specimens cover a growing range of oncology biomarkers, manufactured to precise standards including defined allelic frequencies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CareDx and Horizon Enter into a Collaboration
Horizon’s standards to support proficiency testing of CareDx solid organ transplantation injury monitoring diagnostic assay.
Thursday, June 04, 2015
Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
Grahame brings over 20 years’ experience to Horizon.
Thursday, May 14, 2015
Transgenomic to Incorporate Horizon's Genomic Reference Standards
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits.
Thursday, April 23, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon Discovery Group plc Trading Update
Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering.
Monday, January 19, 2015
Horizon Discovery Group plc Establishes Scientific Advisory Board for Horizon Diagnostics Business Unit
The Scientific Advisory Board will recommend improvements needed in laboratories adopting Companion Diagnostic assays.
Tuesday, November 11, 2014
Horizon Signs Master Services Agreement for Approximately $1.2 Million
Agreement covers development of molecular reference standards for companion diagnostics.
Friday, September 26, 2014
Horizon Reports a Strong First Half
Interim results for the six months ended 30 June 2014 position the company for continued growth.
Tuesday, September 23, 2014
Horizon, LGC Awarded Technology Strategy Board Grant
Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies.
Tuesday, June 17, 2014
Horizon Discovery and Desktop Genetics Collaborate on CRISPR Design Platform
Platform to be used as part of Horizon’s GENESIS suite of gene editing technologies.
Tuesday, December 17, 2013
Horizon Strengthens Board with Appointment of Dr. Ian Gilham
Appointment of Dr. Ian Gilham as non-executive director.
Friday, August 02, 2013
Horizon Discovery and Diatech Pharmacogenetics Sign Distribution Agreement
Agreement covers distribution of Horizon Diagnostics’ molecular reference standards products in Italy, San Marino and Vatican City.
Monday, April 15, 2013
Horizon Receives the Queen’s Award for Enterprise in International Trade
The UK’s most prestigious business award granted in recognition of outstanding achievement in export growth.
Monday, April 23, 2012
UK Translational Genomics Company Horizon Discovery Launches new Companion Diagnostics Venture
New venture will support the development, approval and sale of companion diagnostic products in the field of cancer.
Thursday, January 07, 2010
Scientific News
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!